Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Xencor Inc (NASDAQ:XNCR)

18.86
Delayed Data
As of 10:03am ET
 -0.13 / -0.68%
Today’s Change
9.89
Today|||52-Week Range
24.82
+29.00%
Year-to-Date
Xencor Stock Up On Cancer Drugs Partnership with Novartis
Jun 29 / Zacks.com - Paid Partner Content
Why Xencor Inc's Shares Are Skyrocketing Today
Jun 28 / MotleyFool.com - Paid Partner Content
Biotech Stock Roundup: Gilead Gets FDA Nod for HCV Drug, Regulus Hit by Clinical Hold
Jun 29 / Zacks.com - Paid Partner Content
Strong On High Volume: Xencor (XNCR)
Jun 28 / TheStreet.com - Paid Partner Content

Today’s Trading

Previous close18.99
Today’s open19.00
Day’s range18.70 - 19.13
Volume37,887
Average volume (3 months)255,268
Market cap$773.8M
Dividend yield--
Data as of 10:03am ET, 07/01/2016

Growth & Valuation

Earnings growth (last year)+13.46%
Earnings growth (this year)-96.67%
Earnings growth (next 5 years)--
Revenue growth (last year)+191.62%
P/E ratioNM
Price/Sales20.55
Price/Book4.74

Competitors

 Today’s
change
Today’s
% change
ADROAduro Biotech Inc+0.72+6.37%
ZIOPZIOPHARM Oncology In...+0.09+1.64%
AMPHAmphastar Pharmaceut...+0.15+0.93%
KERXKeryx Biopharmaceuti...+0.15+2.27%
Data as of 10:18am ET, 07/01/2016

Financials

Next reporting dateJuly 28, 2016
EPS forecast (this quarter)-$0.26
Annual revenue (last year)$27.8M
Annual profit (last year)-$17.6M
Net profit margin-63.37%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Bassil I. Dahiyat
Vice President-Finance &
Investor Relations
John J. Kuch
Corporate headquarters
Monrovia, California

Forecasts

Partner Offers

Search for Jobs